OptiBiotix Health yesterday announced it had signed a deal with the University of Reading to start clinical studies on the company’s products.
The deal will cover the start of clinical trials testing OptiBiotix’s first product, a capsular food supplement designed to reduce cholesterol.
The data from the studies, which will involve one of its Lactobacillus cholesterol-lowering strains, are set to be made available by the end of the third quarter of 2015.
“The signing of this contract completes another important milestone in product development as we build up the scientific evidence supporting the value of our products in the prevention and management of lifestyle diseases which cause significant global morbidity and mortality,” said OptiBiotix chief executive Stephen O’Hara.
Shares in the company were down 0.9 per cent to 13.75p.